Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
In a clinical trial for certain patients with advanced urothelial carcinoma, overall survival was prolonged by about 30% by using supportive care plus maintenance treatment with the drug avelumab, versus supportive care alone.
Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.